BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AZD4045 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of AZD4045\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07681596-3202@assetmemo.bio
DTSTAMP:20261121T004542Z
DTSTART;VALUE=DATE:20310306
DTEND;VALUE=DATE:20310307
SUMMARY:AZD4045: Phase 1/2 readout est. (NCT07681596)
DESCRIPTION:AZD4045\, phase 1/2\, Multiple Myeloma.\nStudy: A Modular\, Pha
 se I/II\, Multicentre Study to Evaluate AZD4045\, in Participants With Rel
 apsed or Refractory Multiple Myeloma\nEstimated primary completion: 6 Marc
 h 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/azd4045#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07681596
URL:https://assetmemo.bio/drug/azd4045#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
